Regulatory Spine Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota byTim AllenFebruary 5, 2026
Spine Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield byJosh SandbergApril 28, 2025
Neuro Spine Mainstay Medical Announces Positive Results from the Landmark ReActiv8® RESTORE Clinical Trial byTim AllenJanuary 16, 2025
Neuro Regulatory Mainstay Medical Announces Receipt of European and Australian Approvals of MRI Labeling on ReActiv8® Restorative Neurostimulation System™ byJosh SandbergJuly 9, 2024
Neuro Regulatory Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on ReActiv8® Restorative Neurostimulation System™ byJosh SandbergFebruary 12, 2024
Neuro Spine Mainstay Medical Announces Completion of Enrollment of RESTORE Clinical Trial of ReActiv8® in the United States byJosh SandbergAugust 29, 2023
Neuro Spine Mainstay Medical Announces Publication of Three-Year Clinical Trial Data from Post-Market Clinical Follow-up Registry of ReActiv8® in the United Kingdom byJosh SandbergJuly 20, 2023
Neuro Spine Mainstay Medical announces the release of post-marketing data from the ongoing ReActiv8®-C study in patients with chronic low back pain byChris StewartNovember 23, 2022
Neuro Spine Mainstay Medical Announces Publication of Three-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™ byChris StewartSeptember 29, 2022
Neuro Spine Mainstay Medical Announces Publication of Two-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™ byChris StewartJanuary 6, 2022
